Cantel Medical Names Jorgen B. Hansen as New President and CEO
01 Aug, 2016, 13:00 BST
LITTLE FALLS, New Jersey, Aug. 1, 2016 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE: CMN) announced today the appointment of Jorgen B. Hansen as the Company's President and Chief Executive Officer, effective today, consistent with the Company's long-term CEO succession plan. Mr. Hansen also will become a member of the Board of Directors. Mr. Hansen succeeds Andrew A. Krakauer, who will serve as a Senior Advisor for the Company until October 15, 2016.
Charles M. Diker, Cantel's Chairman of the Board, stated, "We brought Jorgen Hansen to Cantel nearly four years ago. He's a dynamic, experienced leader in the medical device industry who has clearly demonstrated strong leadership and the vision necessary to achieve our full potential. In addition to leading the day-to-day operations for the Company, Jorgen played a key role in the development of our strategic plan including our expansion in international markets and the successful completion of 12 acquisitions. All of these accomplishments have reinforced our confidence in Jorgen's ability to lead the Company as Chief Executive Officer."
Mr. Diker added "I also would like to thank Andy Krakauer for his exceptional service to the Company over the past 12 years. He has been an outstanding leader who helped Cantel achieve exceptional success during his tenure. His contributions and experience in the medical device industry have been invaluable to the Company."
Mr. Hansen joined Cantel in November 2012 as EVP and COO, and was appointed to President and COO in November 2014. He also served as President and CEO of Cantel's Endoscopy business unit, the Company's largest division, from November 2012 to July 2015. Prior to joining Cantel, Mr. Hansen held leadership positions with increasing responsibility in the global medical device industry. He worked at ConvaTec from May 2009 - November 2012, most recently as Senior Vice President, Global Marketing, Business Development, Science and Innovation. Mr. Hansen joined ConvaTec from Coloplast, where he held various leadership roles over a 13-year period in Asia and Europe, ranging from General Manager, Division Head and Senior Vice President of Global Operations. He received a Bachelor of Science Degree in Mechanical Engineering from Denmark Technical University, and an International Commerce degree from the Copenhagen Business School in Denmark.
"I am honored to be appointed as Cantel's CEO and lead this exciting company and talented team," said Mr. Hansen. "I would like to thank Mr. Diker and the Board for this opportunity, and as CEO, I will continue to pursue Cantel's vision to be the global leader in infection prevention. We will do this by executing on our business priorities focused on new products, market expansion and M&A, supported by continuous improvement."
About Cantel Medical
Cantel Medical is a leading global company dedicated to delivering innovative infection prevention products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives. Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates, hollow fiber membrane filtration and separation products. Additionally, we provide technical service for our products.
For further information, visit the Cantel website at www.cantelmedical.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.
Related Links
SOURCE Cantel Medical Corp.